Todd Wider Biography and Net Worth

Director of Abeona Therapeutics


Todd Wider, M.D.became a director in May 2015 and serves as a member of the Audit Committee and Compensation Committee. Dr. Wider is a surgeon and has served as consultant to numerous entities in the biotechnology space. Dr. Wider holds an M.D. from Columbia College of Physicians and a B.A. from Princeton University.

What is Todd Wider's net worth?

The estimated net worth of Todd Wider is at least $3.59 million as of October 26th, 2023. Dr. Wider owns 494,844 shares of Abeona Therapeutics stock worth more than $3,587,619 as of March 29th. This net worth estimate does not reflect any other assets that Dr. Wider may own. Learn More about Todd Wider's net worth.

How do I contact Todd Wider?

The corporate mailing address for Dr. Wider and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Todd Wider's contact information.

Has Todd Wider been buying or selling shares of Abeona Therapeutics?

Todd Wider has not been actively trading shares of Abeona Therapeutics in the last ninety days. Most recently, Todd Wider sold 25,000 shares of the business's stock in a transaction on Thursday, October 7th. The shares were sold at an average price of $0.97, for a transaction totalling $24,250.00. Learn More on Todd Wider's trading history.

Who are Abeona Therapeutics' active insiders?

Abeona Therapeutics' insider roster includes Michael Amoroso (CEO), Edward Carr (CAO), Brendan O'Malley (SVP), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.

Are insiders buying or selling shares of Abeona Therapeutics?

During the last twelve months, Abeona Therapeutics insiders bought shares 2 times. They purchased a total of 23,000 shares worth more than $92,800.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 14,079 shares worth more than $63,728.94. The most recent insider tranaction occured on January, 17th when Director Mark Alvino sold 7,084 shares worth more than $36,199.24. Insiders at Abeona Therapeutics own 5.3% of the company. Learn More about insider trades at Abeona Therapeutics.

Information on this page was last updated on 1/17/2024.

Todd Wider Insider Trading History at Abeona Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2021Sell25,000$0.97$24,250.00View SEC Filing Icon  
2/18/2021Sell321,345$2.34$751,947.30
12/2/2020Sell33,876$1.49$50,475.24920,256View SEC Filing Icon  
11/23/2020Sell17,969$1.33$23,898.77954,132View SEC Filing Icon  
11/2/2020Sell33,876$1.04$35,231.04972,101View SEC Filing Icon  
9/20/2016Buy5,000$5.48$27,400.0075,000View SEC Filing Icon  
See Full Table

Todd Wider Buying and Selling Activity at Abeona Therapeutics

This chart shows Todd Wider's buying and selling at Abeona Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abeona Therapeutics Company Overview

Abeona Therapeutics logo
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Read More

Today's Range

Now: $7.25
Low: $7.10
High: $7.46

50 Day Range

MA: $6.56
Low: $4.07
High: $8.68

2 Week Range

Now: $7.25
Low: $2.65
High: $9.01

Volume

267,314 shs

Average Volume

345,842 shs

Market Capitalization

$198.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49